1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Mesothelin Expression: new trials by email Literature Review of Mesothelin Expression trials Research Report on Mesothelin Expression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) LMB-100, pembrolizumab, Mesothelin Expression - Lung Cancer, Non-Small Cell Lung Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2019-09-11 | 2024-04-16 |
| Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors LMB-100, Nab-Paclitaxel, Mesothelin Expression - Neoplasms, Pancreatic Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2016-08-03 | 2022-03-15 |
Adenocarcinoma of Lung (1) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
National Cancer Institute (NCI) (2)
United States (2)
Azam Ghafoor, M.D. (1) · Christine C Alewine, M.D. (1)